Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PayPal Holdings, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while PayPal Holdings, Inc. trades at $43.98 (market cap $40.27B). The key difference: PayPal Holdings, Inc. is far larger — about 9× ACADIA Pharmaceuticals Inc.'s market cap, and PayPal Holdings, Inc. pays a 1.23% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PYPL | |
|---|---|---|
Market Cap | $4.49B | $40.27B |
Sector | Health | Financials |
52-Week High | $28.06 | $78.22 |
52-Week Low | $20.06 | $39.08 |
Enterprise Value | $3.69B | $40.34B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PayPal trades at $45.65, up 0.4% with a bullish technical outlook. The stock appears undervalued with a P/E of 8.46 and strong profitability metrics including 15% net income margin and 25.12% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow generation of $6.4B from operations. Analyst consensus is mixed with 37% buy ratings but a $49 price target suggesting 7% upside potential.
PayPal presents a value opportunity with attractive valuation multiples and solid fundamentals, though growth moderation and competitive pressures remain concerns. The stock's technical strength and dividend initiation provide support, while legal scrutiny and execution risks warrant monitoring. Upside appears limited near-term but long-term prospects remain favorable if management delivers on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
